Premium
Overexpansion of the 29 mm SAPIEN 3 transcatheter heart valve in patients with large aortic annuli (area > 683 mm 2 ): A case series
Author(s) -
Mathur Moses,
McCabe James M.,
Aldea Gabriel,
Pal Jay,
Don Creighton W.
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27190
Subject(s) - medicine , cardiac skeleton , aortic valve , regurgitation (circulation) , valve replacement , hemodynamics , cardiology , heart valve , nuclear medicine , aortic valve replacement , stenosis
Objectives To evaluate overexpanded 29 mm SAPIEN (S3) transcatheter heart valves in patients with aortic annuli area >683 mm 2 . Background The largest valve area the 29 mm S3 is specified for is 683 mm 2 . Valve overexpansion has been performed in patients with larger aortic annuli, but data are limited. Moreover, feasibility in areas >740 mm 2 is unknown. Methods All 29 mm S3 transcatheter aortic valve replacements (TAVR) at a single center over 23‐months were retrospectively reviewed. Patients with annulus areas >683 mm 2 were included. Immediate post‐TAVR hemodynamics and transthoracic echocardiography (TTE) findings on post‐TAVR day‐1 and day‐30 were recorded. Results Of 81 29 mm S3 TAVR cases, 3 (3.7%) met inclusion criteria (patients 1, 2, and 3 had CT‐scan derived areas of 748.1 mm 2 , 793 mm 2 , and 787 mm 2 , respectively). Annular eccentricity index ranged from 0.12 to 0.25. All underwent transfemoral TAVR with 29 mm S3 valves overexpanded using +4 mL of contrast. Post‐dilatation with +5 mL was performed in patient 2. The average valve shortening was 10.68 mm. On day 1, patients 1 and 2 had trace and mild paravalvular leak (PVL) (respectively), whereas, patient 3 had mild–moderate PVL. Patient 1 was also noted to have trace central AR on day 1. No other central AR was noted. Immediate post‐procedure aortic regurgitation (AR) index in patients 1, 2, and 3 was 43, 34, and 33 respectively. At 30 days, AR was completely resolved in patient 1, whereas AR severity in patients 2 and 3 remained similar. No patients had > moderate AR at any point during follow‐up. No valve migration or embolization occurred. Patient 1 required a permanent pacemaker. No other major complications were noted. All patients were clinically stable at 30 days. Conclusions TAVR using overexpanded 29 mm S3 in valve areas >740 mm 2 (up to 793 mm 2 ) seemed to be safe and feasible in our small series. Further study in a larger series is needed to determine clinical outcomes in this patient population.